CS189680B2 - Method of preparing 3-aryloxy-3-phenylpropyl amines - Google Patents

Method of preparing 3-aryloxy-3-phenylpropyl amines

Info

Publication number
CS189680B2
CS189680B2 CS75150A CS15075A CS189680B2 CS 189680 B2 CS189680 B2 CS 189680B2 CS 75150 A CS75150 A CS 75150A CS 15075 A CS15075 A CS 15075A CS 189680 B2 CS189680 B2 CS 189680B2
Authority
CS
Czechoslovakia
Prior art keywords
phenylpropyl
aryloxy
amines
preparing
phenylpropyl amines
Prior art date
Application number
CS75150A
Other languages
English (en)
Inventor
Bryan B Molloy
Klaus K Schmiegel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26625843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CS189680(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority claimed from KR1019750000261A external-priority patent/KR800001009B1/ko
Priority to CS77248A priority Critical patent/CS189698B2/cs
Priority to CS777781A priority patent/CS196397B2/cs
Publication of CS189680B2 publication Critical patent/CS189680B2/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CS75150A 1974-01-10 1975-01-08 Method of preparing 3-aryloxy-3-phenylpropyl amines CS189680B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CS77248A CS189698B2 (en) 1974-01-10 1977-01-14 Method of preparing 3-aryloxy-3-phenylpropyl amines
CS777781A CS196397B2 (cs) 1974-01-10 1977-11-24 Způsob přípravy 3-aryloxy-3-fenylpropylaminu

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US05/432,379 US4314081A (en) 1974-01-10 1974-01-10 Arloxyphenylpropylamines
KR1019750000261A KR800001009B1 (ko) 1975-01-09 1975-01-09 아릴옥시페닐프로필 아민류의 제조방법

Publications (1)

Publication Number Publication Date
CS189680B2 true CS189680B2 (en) 1979-04-30

Family

ID=26625843

Family Applications (1)

Application Number Title Priority Date Filing Date
CS75150A CS189680B2 (en) 1974-01-10 1975-01-08 Method of preparing 3-aryloxy-3-phenylpropyl amines

Country Status (23)

Country Link
US (1) US4314081A (cs)
JP (1) JPS5939418B2 (cs)
AR (3) AR205577A1 (cs)
AT (1) AT336000B (cs)
BE (1) BE824255A (cs)
BG (3) BG23212A3 (cs)
CA (1) CA1051034A (cs)
CH (1) CH609675A5 (cs)
CS (1) CS189680B2 (cs)
DD (1) DD118613A5 (cs)
DE (1) DE2500110A1 (cs)
DK (1) DK140430B (cs)
ES (1) ES433720A1 (cs)
FR (1) FR2257288B1 (cs)
GB (1) GB1493961A (cs)
IE (1) IE40346B1 (cs)
NL (2) NL181654C (cs)
PH (1) PH11652A (cs)
RO (2) RO69763A (cs)
SE (1) SE412906B (cs)
SU (1) SU1005655A3 (cs)
YU (3) YU36915B (cs)
ZA (1) ZA7532B (cs)

Families Citing this family (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4584404A (en) * 1974-01-10 1986-04-22 Eli Lilly And Company Substituted phenoxyphenylproply dimethylamines
JPS5283811A (en) * 1976-01-01 1977-07-13 Lilly Co Eli Aryloxy phenyl propylamines and their salts
GB1570613A (en) * 1976-10-27 1980-07-02 Akzo Nv Biologically active tricyclic compounds and pharmaceutical compositions containing same
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
FR2455571A2 (fr) * 1979-02-15 1980-11-28 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre medicaments
DE3017812A1 (de) * 1980-05-09 1981-11-12 Merck Patent Gmbh, 6100 Darmstadt Cyclopropanderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US4430319A (en) 1982-05-21 1984-02-07 State University Of New York Radioactive iodine labeled phenolic amines
US4692469A (en) * 1982-09-07 1987-09-08 Ciba-Geigy Corporation Propylamine derivatives
US4824868A (en) * 1982-09-07 1989-04-25 Ciba-Geigy Corporation Propylamine derivatives useful for the treatment of dementia
US4590213A (en) * 1983-04-08 1986-05-20 Eli Lilly And Company Anti-anxiety method
HU207282B (en) * 1984-05-31 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
US4594358A (en) * 1985-02-25 1986-06-10 Eli Lilly And Company Analgesic method
US4683235A (en) * 1985-02-25 1987-07-28 Eli Lilly And Company Analgesic method
US4777291A (en) * 1985-02-27 1988-10-11 Eli Lilly And Company Racemization process
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
US5149714A (en) * 1987-08-14 1992-09-22 Merrell Dow Pharmaceuticals Inc. Antidepressants
US5223540A (en) * 1987-10-22 1993-06-29 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
US4971998A (en) * 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
US4996235A (en) * 1987-11-25 1991-02-26 Eli Lilly And Company 3,4-diphenylbutanamines
US4876282A (en) * 1987-11-25 1989-10-24 Eli Lilly And Company 1-Phenylalkylamines as selective serotonin uptake inhibitors
US5238959A (en) * 1988-04-08 1993-08-24 Eli Lilly And Company 3-phenyloxy-3-phenyl propanamines
CA1337128C (en) * 1988-04-08 1995-09-26 David Wayne Robertson Propanamine derivatives
US5250571A (en) * 1988-11-14 1993-10-05 Eli Lilly And Company (S)-norfluoxetine in method of inhibiting serotonin uptake
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
IT1228209B (it) * 1989-01-10 1991-06-05 Grato Magnone Procedimento per la preparazione di fluoxetina cloridrato.
US5166437A (en) * 1989-03-03 1992-11-24 Orion-Yhtyma Oy Process for the preparation of fluoxetine
FI81083C (fi) * 1989-03-03 1990-09-10 Orion Yhtymae Oy Ett foerbaettrat foerfarande foer framstaellning av n-metyl-3-(p-trifluormetylfenoxi)-3-fenylpropylamin hydroklorid.
DK258389D0 (da) * 1989-05-26 1989-05-26 Ferrosan As Aryloxyphenylpropylaminer, deres fremstilling og anvendelse
JPH0375680U (cs) * 1989-11-21 1991-07-30
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5250572A (en) * 1990-03-29 1993-10-05 Eli Lilly And Company (R)-norfluoxetine in method for occupying serotonin IC receptors
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
CA2061665C (en) * 1991-02-25 2002-04-16 Mark Mortensen Foreman Treatment of lower urinary tract disorders
US5136079A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Regioselective synthesis
US5136078A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Synthesis of b-cyanohydrins
US5320825A (en) * 1991-05-01 1994-06-14 Trustees Of The University Of Pennsylvania Serotonin reuptake inhibitors for S.P.E.C.T. imaging
WO1993000811A1 (en) * 1991-07-01 1993-01-21 The General Hospital Corporation Invertebrate phenylethanolamine transporter and the use thereof
IL99316A (en) 1991-08-27 1995-03-15 Teva Pharma Production of fluoxetine and new intermediates
US5202319A (en) * 1991-09-23 1993-04-13 Hoechst-Roussel Pharmaceuticals Inc. Substituted 3-amino-2,3,4,5-tetrahydro-1-aryloxy-3-benzazepines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
DK0537915T3 (da) * 1991-09-27 1995-11-27 Lilly Co Eli N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
HU9202128D0 (en) * 1992-06-26 1992-10-28 Richter Gedeon Vegyeszet Method for producing n-methyl-(3-phenyl-3-(4-[trifluoro-methyl])-phenooxi-)-amine
EP0576766A1 (en) * 1992-06-29 1994-01-05 Novo Nordisk A/S Propanolamine derivatives, their preparation and use
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US7087765B2 (en) * 1995-06-07 2006-08-08 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
ES2101650B1 (es) * 1995-06-29 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfenoxi) propilamina.
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
ES2101654B1 (es) * 1995-07-24 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
ES2101655B1 (es) * 1995-07-28 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
ES2103680B1 (es) * 1995-08-03 1998-04-01 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3- (p-trifluorometilfenoxi)propilamina.
ES2145977T3 (es) * 1995-08-16 2000-07-16 Lilly Co Eli Potenciacion de la respuesta de la serotonina.
ES2103681B1 (es) * 1995-09-19 1998-04-01 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil - (p-trifluorometilfenoxi) propilamina.
IT1283141B1 (it) * 1996-07-11 1998-04-07 Laporte Organics Francis S P A Procedimento per la preparazione di n-metil-3-(p-trifluorometilfenossi)-3-fenilpropilamina e dei suoi
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5830500A (en) * 1996-07-22 1998-11-03 Pentech Pharmaceuticals, Inc. Low dose fluoxetine tablet
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
TR200001293T2 (tr) * 1997-11-14 2002-09-23 Akzo Nobel N.V. Uykuda solunum durmasını tedavi etmek için mirtazapin kullanımı
US5936124A (en) * 1998-06-22 1999-08-10 Sepacor Inc. Fluoxetine process from benzoylpropionic acid
US6025517A (en) * 1998-08-03 2000-02-15 Sepracor Inc. Fluoxetine process from benzoylacetonitrile
WO2000041684A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company A pharmaceutical combination for the treatment of depression
FR2791345B1 (fr) * 1999-03-26 2001-05-04 Adir Nouveaux derives du benzo[3,4]cyclobuta[1,2-c]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2000058262A1 (en) * 1999-03-29 2000-10-05 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
EP1225881B1 (en) * 1999-09-03 2006-02-22 APBI Holdings, LLC The use of dapoxetine, a rapid-onset selective serotonin reuptake inhibitor, for treating sexual dysfunction
AU1724201A (en) 1999-12-17 2001-06-25 Ranbaxy Laboratories Limited Process for the preparation of fluoxetine hydrochloride
GB0004152D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004149D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
US6273260B1 (en) 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
RU2174391C1 (ru) * 2000-10-24 2001-10-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция с антидепрессантной активностью
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
US6313350B1 (en) 2001-01-31 2001-11-06 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6310250B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form A of fluoxetine hydrochloride
US6310251B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6258853B1 (en) 2001-01-31 2001-07-10 Grayson Walker Stowell Form a of fluoxetine hydrochloride
HRP20030710A2 (en) * 2001-03-06 2004-08-31 Lilly Co Eli Inhibitor of monoamine uptake
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
AR035700A1 (es) * 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
CA2450073C (en) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
MXPA04000979A (es) * 2001-07-31 2005-02-17 Upjohn Co Tratamiento de dolor cronico con 3-ariloxi-3-fenilpropanaminas.
SE0102641D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
US20040170688A1 (en) * 2001-08-06 2004-09-02 Deshmukh Abhijit Mukund Enteric formulation of fluoxetin
CA2457385A1 (en) 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
US6630454B2 (en) 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
ES2666188T3 (es) * 2001-10-12 2018-05-03 Azevan Pharmaceuticals, Inc. Antagonistas del v1a de vasopresina beta-lactámicos
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
PT1455770E (pt) * 2001-11-30 2007-09-06 Lilly Co Eli Uso de inibidores de reabsorção da norepinefrina para o tratamento dos transtornos de tiques.
ES2295435T3 (es) * 2001-12-11 2008-04-16 Eli Lilly And Company Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo.
KR20040088519A (ko) 2002-02-22 2004-10-16 뉴 리버 파마슈티칼스, 인크. 활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법
US7326733B2 (en) * 2002-05-31 2008-02-05 The Forsyth Institute Methods for increasing bone density
JP2004077714A (ja) * 2002-08-15 2004-03-11 Fuji Xerox Co Ltd 光走査装置
SE0203304D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
US6846957B2 (en) * 2002-11-22 2005-01-25 Board Of Regents, The University Of Texas System Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
EP1620083A2 (en) * 2003-04-18 2006-02-01 Pharmacia & Upjohn Company LLC Combination therapies
EP1658283A2 (en) * 2003-05-30 2006-05-24 Ranbaxy Laboratories, Ltd. Substituted pyrrole derivatives and their use as hmg-co inhibitors
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
WO2005011583A2 (en) * 2003-07-28 2005-02-10 Leslie Joe Dunaway Treatment of allergic rhinitis and asthma
CA2537402C (en) 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
CA2539426C (en) * 2003-09-17 2012-07-10 Janssen Pharmaceutica, Nv Fused heterocyclic compounds
DE602004028150D1 (de) * 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
AU2004312059A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
US7893261B2 (en) * 2004-03-26 2011-02-22 Baylor University Serotonin reuptake inhibitors
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
CA2567249A1 (en) * 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Lithium combinations, and uses related thereto
WO2005108683A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006037055A1 (en) * 2004-09-27 2006-04-06 Dr. Reddy's Laboratories Ltd. Synthesis of atomoxetine hydrochloride
US20060194869A1 (en) * 2004-12-23 2006-08-31 Santiago Ini Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
MX2007010931A (es) * 2005-03-08 2007-10-16 Teva Pharma Formas cristalinas de (s)-(+)-n,n-dimetil-3-(1-naftaleniloxi)-3-(2 -tienil)propanamina oxalato y la preparacion ellas.
WO2006099459A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Process for the preparation of optically active (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine
AU2006227199A1 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
CN101203216A (zh) * 2005-04-22 2008-06-18 惠氏公司 二氢苯并呋喃衍生物及其用途
CA2605554A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
AU2006239897A1 (en) * 2005-04-22 2006-11-02 Wyeth Crystal forms of {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
CN101175740A (zh) 2005-04-22 2008-05-07 惠氏公司 二氢苯并呋喃衍生物和其用途
EP2671508B1 (en) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-informatics system
US7485754B2 (en) * 2005-07-08 2009-02-03 Apotex Pharmachem Inc. Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers
NZ565683A (en) * 2005-07-08 2011-04-29 Braincells Inc Methods for identifying agents and conditions that modulate neurogenesis in human neural cells
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
RU2466991C2 (ru) * 2005-07-19 2012-11-20 Эйзеван Фармасьютиклз, Инк. β-ЛАКТАМИЛЗАМЕЩЕННЫЕ АНАЛОГИ ФЕНИЛАЛАНИНА, ЦИСТЕИНА И СЕРИНА В КАЧЕСТВЕ АНТАГОНИСТОВ ВАЗОПРЕССИНА
US20070042034A1 (en) * 2005-07-22 2007-02-22 Myriad Genetics, Incorporated High drug load formulations and dosage forms
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US20080207923A1 (en) * 2005-09-22 2008-08-28 Santiago Ini Pure DNT-maleate and methods of preparation thereof
US7842717B2 (en) * 2005-09-22 2010-11-30 Teva Pharmaceutical Industries Ltd. DNT-maleate and methods of preparation thereof
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
CN1304360C (zh) * 2005-12-12 2007-03-14 天津大学 N,n－二甲基－3－羟基－3－芳基丙胺的制备方法
EP1844034A1 (en) * 2006-01-23 2007-10-17 Teva Pharmaceutical Industries Ltd Dnt-fumarate and methods of preparation thereof
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
PA8720801A1 (es) * 2006-03-24 2008-11-19 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento de la depresion
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
WO2007139984A2 (en) * 2006-05-23 2007-12-06 Teva Pharmaceutical Industries Ltd. Duloxetine hcl polymorphs
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
US20080153896A1 (en) * 2006-07-14 2008-06-26 Gyan Chand Yadav Polymorphic Forms of an HMG-CoA Reductase Inhibitor and Uses Thereof
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
WO2008026227A2 (en) * 2006-08-28 2008-03-06 Matrix Laboratories Ltd A process for the preparation of atomoxetine hydrochloride
JP2010502722A (ja) * 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ITMI20061987A1 (it) * 2006-10-16 2008-04-17 Archimica Srl Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine.
WO2008062473A1 (en) * 2006-10-31 2008-05-29 Cadila Healthcare Limited Process for preparing atomoxetine hydrochloride
FR2910319B1 (fr) 2006-12-20 2011-06-03 Substipharm Dev Formulations pharmaceutiques dispersibles contenant de la fluoxetine
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
EP2125017A2 (en) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation of neurogenesis with use of modafinil
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
EP2217073B1 (en) 2007-06-21 2019-10-09 VeroScience LLC Method of treating metabolic disorders and depression with dopamine receptor agonists
WO2009141833A2 (en) * 2008-04-17 2009-11-26 Ind-Swift Laboratories Limited An improved process for synthesizing highly pure atomoxetine
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
CN102316902B (zh) 2009-02-20 2014-09-24 to-BBB控股股份有限公司 基于谷胱甘肽的药物递送系统
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
IL255113B (en) 2009-05-06 2022-09-01 Laboratory Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
WO2011027359A2 (en) 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
EP2348120B1 (en) 2009-12-30 2014-06-11 Universität Wien Enzymatic reduction of 1-phenylpropanone and derivatives thereof
ES2858499T3 (es) 2010-07-01 2021-09-30 Azevan Pharmaceuticals Inc Compuestos para su uso en el tratamiento de trastorno explosivo intermitente
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
BR112013023810A2 (pt) 2011-03-17 2016-12-13 Lupin Ltd composições farmacêuticas de liberação controlada de inibidores seletivos da recaptação de serotonina
US20150190352A1 (en) 2012-07-31 2015-07-09 Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret Anonim Sirketi Use of fluoxetine in animals
EA201590047A1 (ru) 2012-07-31 2015-09-30 Сановел Хайван Саглиги Юрюнлери Санайи Ве Тиджарет А.С. Применение флуоксетина для увеличения мясной и молочной продуктивности
WO2014046544A1 (en) 2012-09-21 2014-03-27 Aapa B.V. Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators
SG10202001065SA (en) 2014-03-28 2020-04-29 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
CN105777706B (zh) * 2014-12-25 2019-08-23 江苏恩华药业股份有限公司 一种3-[(苯并[d][1, 3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用
CA3075759A1 (en) 2017-09-15 2019-03-21 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury
JP7739256B2 (ja) 2019-07-19 2025-09-16 バイオエクセル セラピューティクス，インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683742A (en) * 1951-02-23 1954-07-13 Searle & Co Nu, nu-disubstituted omega-arylmethoxy-omega-arylalkylamine derivatives
ES251290A1 (es) * 1958-08-21 1960-04-01 Parke Davis & Co Un procedimiento para la producciën de alcohilaminas arilsustituidas
US3132179A (en) * 1959-08-27 1964-05-05 Sterling Drug Inc Ethers of alpha-hydroxymethyl-beta-monocarbocyclic aryl ethyl amines and their preparation
US3253040A (en) * 1962-12-10 1966-05-24 Union Carbide Corp Process for the production of primary 3-hydrocarbyloxypropylamines

Also Published As

Publication number Publication date
YU37307B (en) 1984-08-31
YU37308B (en) 1984-08-31
ZA7532B (en) 1976-08-25
AT336000B (de) 1977-04-12
AR205633A1 (es) 1976-05-21
YU36915B (en) 1984-08-31
RO69763A (ro) 1982-02-26
FR2257288A1 (cs) 1975-08-08
DE2500110C2 (cs) 1987-06-11
SU1005655A3 (ru) 1983-03-15
BG23212A3 (bg) 1977-07-12
NL930108I2 (nl) 1994-08-16
DK140430C (cs) 1980-01-21
DK140430B (da) 1979-08-27
AU7683674A (en) 1976-06-24
GB1493961A (en) 1977-12-07
BE824255A (fr) 1975-07-09
JPS50101333A (cs) 1975-08-11
BG60761B2 (bg) 1996-02-29
US4314081A (en) 1982-02-02
NL181654B (nl) 1987-05-04
RO70660A (ro) 1983-09-26
CH609675A5 (cs) 1979-03-15
NL181654C (nl) 1987-10-01
NL7500186A (nl) 1975-07-14
YU3275A (en) 1982-06-18
BG26192A3 (bg) 1979-02-15
YU121481A (en) 1983-04-27
ATA10275A (de) 1976-08-15
ES433720A1 (es) 1976-12-01
AR205577A1 (es) 1976-05-14
AR205578A1 (es) 1976-05-14
PH11652A (en) 1978-05-08
CA1051034A (en) 1979-03-20
IE40346B1 (en) 1979-05-09
DE2500110A1 (de) 1975-07-17
RO70660B (ro) 1983-08-30
JPS5939418B2 (ja) 1984-09-22
SE412906B (sv) 1980-03-24
FR2257288B1 (cs) 1978-07-21
YU121581A (en) 1983-04-27
IE40346L (en) 1975-07-10
SE7500215L (cs) 1975-07-11
DD118613A5 (cs) 1976-03-12
DK688974A (cs) 1975-09-01
NL930108I1 (nl) 1993-10-18

Similar Documents

Publication Publication Date Title
CS189680B2 (en) Method of preparing 3-aryloxy-3-phenylpropyl amines
BG24812A3 (en) Method of obtaining 8-thiomethylergolins
ZA756036B (en) Method of preparing mercaptans
BG24542A3 (en) Method of preparing carbonylaldiminomethanphosphonates
YU105275A (en) Process for preparing phenylalkyl amines
CS191882B2 (en) Method of preparing 7-methoxy-6-thia-tetracycline
CS189726B2 (en) Method of producing new amines
EG11666A (en) Process for preparation of a-6-deoxy-5-hydroxytetracyclin
AR214315A1 (es) Metodo de preparacion de fenetil-alquil-aminas terciarias
EG11061A (en) Process for preparation of 3-fluorocephalosporins
JPS51125089A (en) Preparation method of piperazinopyrimidine derivatives
IL48565A0 (en) Method of preparation of 3-methylenecephams
CS191954B2 (en) Method of preparing 3-acetoxy-3,7-dimethyl-6-octennitrile
BG27376A3 (en) Method of obtaining of ureidesubstiputed cefalosporines
SU576953A1 (en) Method of preparing tertiary phosphinoxides
CS189698B2 (en) Method of preparing 3-aryloxy-3-phenylpropyl amines
CS185673B2 (en) Method of producing new amines
CS191953B2 (en) Method of preparing 3,7-dimethyl-3-hydroxy-6-octennitrile
CS182828B2 (en) Method of preparing disazopigments
CS181170B2 (en) Method of preparing 5-methyl-2-nitrophenol
BG23804A1 (en) Method of preparing streptocinase
CS189744B2 (en) Method of producing novel amines
ZA757455B (en) Method of preparation of 3-methylenecephams
CS190440B2 (en) Method of preparing 2-methyl-2-phenyl-5-methoxy-6,7-dichlor-1-indanone
KR780000607B1 (en) Process for preparation of n-phenylpyroles